KEYTRUDA® (pembrolizumab) metastatic oesophageal cancer combination treatment diary

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 2.04 MB

This downloadable diary has been designed for HCPs like yourself, to provide your patients already on/or recently prescribed KEYTRUDA in combination with chemotherapy for metastatic oesophageal cancer.

This diary contains information about KEYTRUDA in combination with chemotherapy for metastatic oesophageal cancer, including its method of administration, mode of action, possible side-effects and what the patient should do if they notice any signs or symptoms. It is also designed to support your consultations with a patient by providing space to record any questions the patient may have, record their future appointment dates and to help support the patient monitor adverse events and safety related issues.

More information about KEYTRUDA® (pembrolizumab)

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website